PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice
Cell Reports · 2025-08 · 44 (8) · 116130
DOI: 10.1016/j.celrep.2025.116130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-08. Verfasst von Jiashu Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA; Department of Medicine and Department of Chemistry, The Univ…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, STAT1 Transcription Factor, STAT2 Transcription Factor, Poly(ADP-ribose) Polymerases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The regulation of type I interferon signaling is crucial for precisely tuning the innate immune response to combat pathogen invasions, fight cancer, and prevent autoimmune diseases. PARP7, a mono-ADP-ribosyltransferase also called TiPARP (tetrachlorodibenzo-p-dioxin [TCDD]-inducible PARP), is reported to inhibit the production of type I interferons. Here, we find that PARP7 suppresses type I interferon signaling instead of interferon production. PARP7 ADP-ribosylates and promotes the ubiquitination of signal transducer and activator of transcription 1 (STAT1) and STAT2, which recruits p62 to promote the degradation of STAT1 and STAT2 through autophagy. By reducing STAT1 and STAT2 levels, PARP7 decreases type I interferon signaling. We further show that the inhibition of PARP7 promotes type I interferon signaling and relieves experimental autoimmune encephalomyelitis (EAE) symptoms in mice. Our findings revealed a molecular mechanism via which PARP7 suppresses type I interferon signaling, offering insights into the immune-modulatory function of PARP7 and suggesting PARP7 inhibition as a potential treatment strategy for multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA; Department of Medicine and Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA.
- Department of Medicine and Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
- Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
- Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway; Department of Pharmacology and Toxicology, University of Toronto, 1 King's Col…
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA; Department of Medicine and Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Insti…
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Xu, J., Yu, T., Yue, Z., Lu, X., Zhang, Y., Wang, L., Åhrling, S. S., Smith, M. R., Li, Y. C., Matthews, J., & Lin, H. (2025). PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice. Cell Reports, 44(8), 116130. https://doi.org/10.1016/j.celrep.2025.116130
Vancouver
Xu J, Yu T, Yue Z, Lu X, Zhang Y, Wang L, et al. PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice. Cell Reports. 2025;44(8):116130. doi:10.1016/j.celrep.2025.116130
BibTeX
@article{Xu2025,
author = {Xu, Jiashu and Yu, Tao and Yue, Zongwei and Lu, Xuan and Zhang, Yandong and Wang, Lei and Åhrling, Samaneh Shabani and Smith, Michael R and Li, Yan Chun and Matthews, Jason and Lin, Hening},
title = {PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {8},
pages = {116130},
doi = {10.1016/j.celrep.2025.116130}
}
EUVIMED